01:49 PM EDT, 08/15/2024 (MT Newswires) -- Cingulate ( CING ) said Thursday it got a European patent for its lead asset CTx-1301, or dexmethylphenidate, to treat attention deficit hyperactivity disorder.

The stock tripled as intraday volume topped 77.5 million shares versus the daily average of about 68,000.

AST SpaceMobile's ( ASTS ) profile is improving with the planned launch of its first five commercial satellites in the first half of September, UBS said in a note.

"With greater conviction in the commercialization and scalability of AST's plans, we are increasing estimates and now look for $1.8 billion of revenue by 2028 (from $1.1 billion prior)," the firm said. UBS lifted the company's share-price target to $30 from $13 and maintained its buy rating.

Shares of AST, which reported its Q2 results late Wednesday, surged 51% as volume topped 47.6 million versus the daily average of about 14.2 million.

Tempest Therapeutics ( TPST ) said it received "positive feedback" from its end-of-phase-2 meeting with the US Food and Drug Administration for amezalpat in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma.

Shares advanced 39% as volume topped 95.8 million versus the daily average of 1.21 million.

Price: 5.59, Change: +3.74, Percent Change: +202.16